ESTRO 2024 - Abstract Book

S1780

Clinical - Lung

ESTRO 2024

Results:

Among a total of 230 lesions (118 right sided and 112 left sided) we found 10 lesions with volumes overlap -6 pts- (equally divided between right and left), 3 of which belong to a single patient and categorized those cases as re-RT type 1 group. Among this group, median re-RT dose was 50Gy (range 32.5-55) delivered in 5 fractions. Treatment was delivered every other day and prescribed at 80% isodose-line. Time interval between re-RT was at least 6 months with a maximum of almost 3 years. Primary was lower gastro-intestinal (GI) tumour in 3 pts, lung tumour in 2 pts and hepatocarcinoma (HCC) in one pt. Two re-irradiated targets were centrally located. All pts well tolerated SBRT with CK and none of them experienced severe toxicity (in particular no fatal bronchial bleeding and/or fistulae were recorded in central targets). One of the 2 pts with centrally located target reported onset of cough (grade 1) few weeks after re-RT.

Conclusion:

SBRT with CK system seems to be safe and feasible in the setting of lung re-irradiation especially in the scenario of volumes overlap. It indeed allows a good compromise between high dose to the target and organ at risk sparing. However, due to the retrospective nature of our analysis as well as to the lack of clinical and radiobiological data, prospective trials are needed to build high-quality evidence.

Keywords: reirradiation, lung cancer, cyberknife

2763

Digital Poster

Socioeconomic disparities in lung cancer: The impact of symptom-to-diagnosis time

Azadeh Abravan, Corinne Faivre-Finn, Marcel van Herk, Gareth Price

The University of Manchester, Radiotherapy related research, Manchester, United Kingdom

Purpose/Objective:

Understanding socioeconomic disparities in cancer outcomes is of importance for effective intervention strategies. This study investigates the association between socioeconomic variations, the stage at which cancer is diagnosed, and the time interval between patients reporting symptoms and the date of diagnosis (diagnostic interval) among individuals with lung cancer.

Material/Methods:

Made with FlippingBook - Online Brochure Maker